Deprecated: Function WP_Dependencies->add_data() was called with an argument that is deprecated since version 6.9.0! IE conditional comments are ignored by all supported browsers. in /home/foxlogica/public_html/psx/wp-includes/functions.php on line 6131
ABOT - FoxLogica

, ,

⏸️ ABOT: HOLD Signal (5/10) – Appointment of Director

⚡ Flash Summary

Abbott Laboratories (Pakistan) Limited announced the appointment of Mr. Brian William Jordan as Director, effective November 25th, 2025. The announcement was made to the General Manager of the Pakistan Stock Exchange Limited, requesting them to inform the TRE Certificate Holders of the Exchange. The notice was signed by Muhammad Usama Jamil, Company Secretary. This appointment might lead to strategic shifts within the company.

Signal: HOLD ⏸️
Strength: 5/10
Sentiment: NEUTRAL
Time Horizon: MEDIUM_TERM

📌 Key Takeaways

  • 🗓️ Appointment Date: Mr. Brian William Jordan appointed as Director effective November 25th, 2025.
  • 🏢 Company: Abbott Laboratories (Pakistan) Limited.
  • ✉️ Recipient: Pakistan Stock Exchange Limited.
  • 🤝 Communication: Request to inform TRE Certificate Holders.
  • ✍️ Signatory: Muhammad Usama Jamil, Company Secretary.
  • 📍 City Office: 11th & 12th Floors, Ocean Tower, Karachi.
  • 🏢 Registered Office: Opp. Radio Pakistan Transmission Centre, Hyderabad Road, Landhi, Karachi.
  • 📞 City Office Contact: +92-21-38709369, +92-21-32799018.
  • 📞 Registered Office Contact: +92-21-111-Abbott (111-222-688).
  • ✉️ P.O. Box (City Office): P.O. Box No. 13841, Karachi.
  • ✉️ P.O. Box (Registered Office): P.O. Box 7229 Karachi 74400.

🎯 Investment Thesis

HOLD. The appointment of a new director doesn’t provide enough information to change the rating. Monitoring Mr. Jordan’s strategic impact will be necessary. Price target and time horizon cannot be assessed based on this announcement alone.

View Original PDF

Disclaimer: AI-generated analysis. Not financial advice.

Written by: FoxLogica News Analysis

Published on: November 25, 2025

📈 ABOT: BUY Signal (7/10) – Financial Results for the Quarter Ended September 30, 2025

⚡ Flash Summary

Abbott Laboratories (Pakistan) Limited reported a strong performance for the quarter ended September 30, 2025. Sales increased significantly compared to the same period last year, driving higher profitability. Net profit for the period grew, supported by effective cost management and increased operational efficiency. The company’s earnings per share (EPS) also saw a notable rise, reflecting improved shareholder value.

Signal: BUY 📈
Strength: 7/10
Sentiment: POSITIVE
Time Horizon: MEDIUM_TERM

📌 Key Takeaways

  • 📈 Sales-Net increased to PKR 56.23 billion for the nine months ended September 30, 2025, compared to PKR 49.56 billion in 2024.
  • 🌍 Export sales grew slightly to PKR 2.32 billion from PKR 2.29 billion year-over-year.
  • 💰 Gross profit rose to PKR 19.34 billion for the nine months, up from PKR 14.07 billion in the previous year.
  • 📊 Basic and diluted earnings per share increased to PKR 54.81 from PKR 40.34 year-over-year.
  • 📉 Finance costs decreased to PKR 55.36 million from PKR 18.59 million.
  • 🏢 Profit before taxation significantly improved to PKR 9.16 billion from PKR 6.04 billion.
  • 💸 Net profit for the period jumped to PKR 5.37 billion from PKR 3.95 billion.
  • 🧪 Local sales increased to PKR 53.91 billion for the nine months, compared to PKR 47.27 billion in 2024.
  • ⚠️ Selling and distribution expenses increased to PKR 8.50 billion from PKR 7.12 billion.
  • ✅ Other income increased to PKR 603.34 million from PKR 541.11 million.
  • 🏦 Cash and cash equivalents increased to PKR 9.01 billion as of September 30, 2025, from PKR 6.18 billion at the end of 2024.

🎯 Investment Thesis

Based on the strong financial results and improved profitability, a BUY recommendation is warranted. The company’s increased sales, efficient cost management, and strong cash position make it an attractive investment. A price target of PKR 65 per share is set, with a time horizon of 12 months, assuming the company continues to maintain its growth trajectory and manage its operational efficiencies.

View Original PDF

Disclaimer: AI-generated analysis. Not financial advice.

Written by: FoxLogica News Analysis

Published on: November 7, 2025

⏸️ ABOT: HOLD Signal (5/10) – Transmission of Quarterly Reports for the Period Ended September 30, 2025

⚡ Flash Summary

ABOT announced: Transmission of Quarterly Reports for the Period Ended September 30, 2025. Basic analysis suggests neutral sentiment. Professional review recommended.

Signal: HOLD ⏸️
Strength: 5/10
Sentiment: NEUTRAL
Time Horizon: MEDIUM_TERM

📌 Key Takeaways

  • ABOT made announcement: Transmission of Quarterly Reports for the Period Ended September 30, 2025
  • Automated analysis: HOLD signal detected
  • Signal strength: 5/10
  • This is basic analysis – manual review recommended
  • Professional CFA analysis unavailable

🎯 Investment Thesis

Basic HOLD indication for ABOT. Manual verification required.

View Original PDF

Disclaimer: AI-generated analysis. Not financial advice.

Written by: FoxLogica News Analysis

Published on: November 6, 2025

⏸️ ABOT: HOLD Signal (5/10) – Board Meeting

⚡ Flash Summary

Abbott Laboratories (Pakistan) Limited has announced a board meeting to be held on October 29th, 2025, to consider the quarterly accounts for the period ending September 30th, 2025. In compliance with PSX Regulations, the company has declared a “Close Period” from October 22nd to October 29th, 2025, during which no Director, CEO, or Executive can deal in the company’s shares. The announcement was made to the Pakistan Stock Exchange, and TRE Certificate Holders of the Exchange are also to be informed.

Signal: HOLD ⏸️
Strength: 5/10
Sentiment: NEUTRAL
Time Horizon: MEDIUM_TERM

📌 Key Takeaways

  • 🗓️ Board meeting scheduled for October 29th, 2025.
  • 🏢 Meeting to consider quarterly accounts ending September 30th, 2025.
  • 🔒 “Close Period” declared from October 22nd to October 29th, 2025.
  • 🚫 No trading by Directors, CEO, or Executives during the “Close Period”.
  • 📜 Compliance with Clause 5.6.4 of PSX Regulations.
  • 📢 Announcement to the Pakistan Stock Exchange.
  • ✉️ TRE Certificate Holders to be informed.
  • 📍 Abbott Laboratories (Pakistan) Limited is the reporting entity.
  • 👤 Muhammad Usama Jamil is the Company Secretary.
  • virtual meeting for quarterly results
  • 🔒 no trading allowed for executives during the closed period

🎯 Investment Thesis

Given the lack of financial details in this announcement, a HOLD recommendation is appropriate. Awaiting the release of quarterly results is crucial to properly assess the company’s performance and revise the investment thesis accordingly. The board meeting will provide additional information.

View Original PDF

Disclaimer: AI-generated analysis. Not financial advice.

Written by: FoxLogica News Analysis

Published on: October 22, 2025